2000
DOI: 10.1042/bst028a010b
|View full text |Cite
|
Sign up to set email alerts
|

The molecular basis of lysosomal storage diseases and their treatment

Abstract: By presenting the liver with lower collagenase exposure than for the isolation of conventional single hepatocytes (singlets), a preparation is obtained containing -20% of hepatocytes which have not separated from their neighhour at the junctional complex and thus remain as pairs (couplets. doublets) or small multiples; subsequent centrifugal clutriation can enrich the proportion of couplets to -70%.The junctions between the adjacent cells in the couplet are repaired during short-term (4-5h) culture; a sulcd ca… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
47
0

Year Published

2002
2002
2022
2022

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 35 publications
(48 citation statements)
references
References 0 publications
1
47
0
Order By: Relevance
“…Lysosomal storage diseases involve dysfunction of one of the more than 50 enzymes in the lysosome, resulting in the accumulation of the associated uncatabolized substrate (Neufeld 1991;Winchester et al 2000) or toxic intermediates (Suzuki et al 2003). A majority of lysosomal storage diseases affect the CNS and disease presentation can range from severe and consistent to mild and variable depending on the enzyme involved, the severity of the mutation, and the species concerned.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Lysosomal storage diseases involve dysfunction of one of the more than 50 enzymes in the lysosome, resulting in the accumulation of the associated uncatabolized substrate (Neufeld 1991;Winchester et al 2000) or toxic intermediates (Suzuki et al 2003). A majority of lysosomal storage diseases affect the CNS and disease presentation can range from severe and consistent to mild and variable depending on the enzyme involved, the severity of the mutation, and the species concerned.…”
Section: Discussionmentioning
confidence: 99%
“…This autosomal recessive inherited disorder of glycoprotein catabolism is caused by a deficiency of the lysosomal enzyme b-mannosidase (MANBA; EC 3.2.1.25, 609489). MANBA acts exclusively at the last step of oligosaccharide catabolism in glycoprotein degradation and functions to cleave the b-linked mannose sugar found in N-linked oligosaccharides of glycoproteins (Neufeld 1991;Winchester et al 2000). b-Mannosidosis is characterized by the intracellular accumulation of small oligosaccharides (mainly disaccharides and trisaccharides) in selected cell types (Jones and Laine 1981).…”
mentioning
confidence: 99%
“…During the last two decades many pathological conditions have been identified as lysosomal storage diseases (Winchester et al, 2000). These include genetic deficiencies in specific lysosomal enzymes, in modifications required for the transport of these enzymes to lysosomes, and in proteins required for the biogenesis of lysosomes and/or lysosome-related organelles.…”
Section: Dysfunctional Mhc Class II Compartments and Melanosomes In Gmentioning
confidence: 99%
“…An enantioselective synthesis of L-fucose-type gem-diamine 1-Niminosugars from D-ribono-g-lactone was developed that used the Mitsunobu reaction on an aminal in the gem-diamine 1-N-iminopyranose ring formation (74)(75) and a stereospecific reduction of an exo-methylene group to form the correct configuration of L-fucose (75-76) (Scheme 6). 24,25 The synthesis of the pivotal intermediate, Intermediates prepared during the total synthetic route to uronic acid-type gem-diamine 1-N-iminosugars are also available for the synthesis of various kinds of glycose and glycosamine-type gem-diamine 1-N-iminoisugars (Scheme 7).…”
Section: Synthesismentioning
confidence: 99%